HR 679
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 4:36 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill aims to reverse changes made by the Food and Drug Administration (FDA) in January 2023 regarding the mifepristone abortion pill. Specifically, it seeks to undo the FDA’s removal of the requirement that mifepristone be dispensed in person and the subsequent certification requirement for pharmacies. The bill intends to restore the previous REMS (Risk Evaluation and Mitigation Strategy) rules, which limited access to the medication to healthcare facilities. It also prohibits the FDA from implementing similar changes in the future.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.